Oppenheimer raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $12 and keeps an Outperform rating on the shares. The firm says stellar Phase 2 results in refractory chronic cough set Trevi on course toward what it believes is a $3B peak U.S. sales potential among refractory to current/emerging standard-of-care. Oppenheimer looks forward to next quarter’s Phase 2b CORAL readout to provide further support.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics price target raised to $12.50 from $7.50 at H.C. Wainwright
- Haduvio’s Promising Efficacy in RCC Drives Buy Rating and Increased Price Target
- Trevi Therapeutics price target raised to $11 from $7 at Leerink
- Trevi Therapeutics price target raised to $25 from $8 at Needham
- Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James